NIH Director visits the Hepatitis B Foundation, Blumberg Institute and Pennsylvania Biotechnology Center

The Hepatitis B Foundation, Blumberg Institute and PABC recently welcomed NIH Director Jay Bhattacharya, MD, PhD, for a visit highlighting collaborative research, innovation and academic programs advancing public health and biomedical discovery.

 

U.S. Rep. Brian Fitzpatrick of Bucks County arranged the event and accompanied Dr. Bhattacharya on a tour of the PABC campus, which houses all three nonprofits. The NIH director and Congressman participated in a roundtable discussion with CEOs from three long-time PABC member companies and leadership from the host organizations.

 

Leaders from our three organizations emphasized the importance of strong partnerships among government, research institutions and industry to translate scientific discovery into real-world solutions that improve public health.

 

More here.

Lou Kassa III, MPA, recognized on

Philadelphia Business Journals Power 100

For the fourth straight year, Louis P. Kassa III, MPA, chief executive officer of the Hepatitis B Foundation, Baruch S. Blumberg Institute and Pennsylvania Biotechnology Center (PABC), has been chosen by the Philadelphia Business Journal for its 2026 Power 100 list, which can be found here.

Detection and characterization of Hepatitis B virus double-stranded linear DNA-derieved covalently closed circular DNA in

chronic hepatitis B patients

This study examined double-stranded linear DNA–derived covalently closed circular DNA (dsl-cccDNA) in patients with Chronic Hepatitis B. Using next-generation sequencing of liver biopsy samples, the researchers identified multiple dsl-cccDNA variants with insertions and deletions near the DR1/DR2 regions of the viral genome. Read more here.

Blumberg Institute presents 2025 Lam Excellence in

Medicinal and Chemistry Award

The Blumberg Institute presented the 2025 Lam Excellence in Medicinal and Chemistry Award recently to Dan Nguyen, BS, senior research scientist in medicinal chemistry, Blumberg Institute and Mark E. McDonell, PhD, director of chemistry, Fox Chase Therapeutics Discovery.

 

The Blumberg Institute presents the Lam Excellence in Medicinal and Chemistry Award annually in honor of Patrick Y. S. Lam, PhD, distinguished professor at the Blumberg Institute. More here.

Blumberg Institute Awarded NIH R21 Grant to Advance

Hepatitis B Research

The Blumberg Institute has received a new two-year $275,000 NIH R21 grant (Grant Number: 1R21AI196369-01) to support innovative research aimed at uncovering key cellular factors involved in Hepatitis B virus infection.


The project, led by Principal Investigator Dr. Liudi Tang, is titled “Identification of Cellular Functions Involved in Hepatitis B Virus Infection via a Novel RNA Sensing and Editing–Dependent Reporter System.”

The award was issued on Feb. 10.

Hepion Pharmaceuticals in-licenses ctRNA Biomarker assay to facilitate early diagnosis and surveillance of Hepatocellular Carcinoma 

Hepion Pharmaceuticals, Inc., a precision diagnostics company, recently announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA (ctRNA) to facilitate early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients (cirrhosis).


Most cases of liver cancer (75-90%) are HCC, and HCC is the sixth most common cancer worldwide, with a high mortality-to incidence ratio that makes it the third deadliest cancer globally. Cirna Diagnostics is a spinout company from the Blumberg Institute. More here.

Blumberg Institute announces a gift from

Distinguished Professor Richard Pestell

The Blumberg Institute has received a generous gift from Distinguished Professor Richard G. Pestell, AO., MD, PhD FACP, FRACP, MBA.

 

Dr. Pestell assigned the Blumberg Institute an equity position in his company StromaGenesis, which is valued at $88 million, two years ago and recently increased that equity position. He previously made another equity-based gift for another of his startup companies. Dr. Pestell previously assigned an equity position in his company ProstaGene shortly before its sale in 2018, which benefited research programs at the Blumberg Institute. These forward-thinking acts of philanthropy support the Institute’s mission and demonstrate Dr. Pestell’s passion for the Institute’s scientific research and drug development work. More here.

Biotech Insiders: Ep. 17

This episode features updates about the state of biotech, NIH funding and some of the latest news shaping the biotech industry in our region.

 

The second half features Heather Steinman, PhD, MBA, senior vice president, business development and executive director of technology transfer at The Wistar Institute, and Carole Burns, PhD, director of innovation and entrepreneurship at the Blumberg Institute. They discuss the future of tech transfer along with some key advice to our listeners.

Listen here.

The Blumberg Institute focuses on understanding the pathobiology of hepatitis B virus and related diseases, developing diagnostics for early detection of liver disease and the discovery of therapeutics, antivirals and immune modulators, aimed at curing hepatitis B and other severe viral diseases.

www.blumberginstitute.org

Linkedin